US Pharma MarketingRethinking the path to IND: How an integrated, global approach can accelerate biologics development
Rethinking the path to IND: How an integrated, global approach can accelerate biologics development is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Thermo Fisher’s future US-based option for biologic and sterile fill-finish manufacturing will help to alleviate capacity bottlenecks globally.
Source: FierceBiotech